51 – 60 of 70
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Immune modulation via T regulatory cell enhancement : Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)
- Contribution to journal › Article
-
Mark
Crosstalk between mast cells and lung fibroblasts is modified by alveolar extracellular matrix and influences epithelial migration
- Contribution to journal › Article
-
Mark
Wtreatment of copd with long-acting bronchodilators : Association between early and longer-term clinically important improvement
- Contribution to journal › Article
-
Mark
Lung Mast Cells Have a High Constitutive Expression of Carboxypeptidase A3 mRNA That Is Independent from Granule-Stored CPA3
- Contribution to journal › Article
-
Mark
Dual bronchodilator therapy as first-line treatment in maintenance-naïve patients with symptomatic copd : A pre-specified analysis of the emax trial
- Contribution to journal › Article
- 2020
-
Mark
Salbutamol use in relation to maintenance bronchodilator efficacy in COPD : a prospective subgroup analysis of the EMAX trial
- Contribution to journal › Article
-
Mark
Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity : Common molecular pathways in Covid-19 and pulmonary fibrosis
- Contribution to journal › Article
-
Mark
Allergic respiratory disease care in the COVID-19 era : A EUFOREA statement
- Contribution to journal › Letter
-
Mark
Type 2 inflammatory biomarker response after exercise challenge testing
- Contribution to journal › Article
-
Mark
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators : an analysis of the EMAX randomised controlled trial
- Contribution to journal › Article
